Skye Bioscience (FRA:09R) Tax Provision: €-0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R Skye Bioscience Inc FRA:09R
19 GF Score
Price €0.51
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Tax Provision?

Skye Bioscience FRA:09R -2.86% 19 Tax Provision is €-0.00 Mil as of Mar. 2026. GuruFocus rates FRA:09R with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Skye Bioscience's tax provision for the three months ended in Mar. 2026 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00 Mil.

Skye Bioscience Tax Provision Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Tax Provision Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.01 -0.00 -0.01 -0.00

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00
FRA:09R
19GF Score
Skye Bioscience Inc FRA:09R
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-0.00 Mil mean?
Skye Bioscience (FRA:09R) has a Tax Provision of €-0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Tax Provision too high?
Skye Bioscience's current Tax Provision is €-0.00 Mil. Overall, Skye Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Tax Provision compare to PLRZ and NEUP?
Skye Bioscience's Tax Provision of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Tax Provision is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Tax Provision of €-0.00 Mil. The current Tax Provision is €-0.00 Mil. Skye Bioscience's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Tax Provision is €-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score

Get the complete analysis for FRA:09R

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price